FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2020– Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Tazverik (tazemetostat) for the treatment of adults and pediatric… Read More »